Planned sale

Mineralys Therapeutics (MLYS): Officer filed to sell ~$78K

Rodman David Malcom, Officer at Mineralys Therapeutics, filed to sell ~$78K of Mineralys Therapeutics shares.

~$78K
planned to sell · 3,542 shares, around Oct 13, 2026
Planned for
Oct 13, 2026
Notice filed
Oct 13, 2026

What stands out in this filing

  • The planned sale is less than 0.01% of the company's shares outstanding.
  • How the shares were acquired, per the notice: Exercise of employee stock options.
  • The notice says the shares were received as pay (stock awards or options).
  • Broker named on the notice: Merrill Lynch.
  • A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 22, 2026InsiderDirector sold ~$3.01M of MLYS shares in the open market
  2. Sep 30, 2026Insider · Their largest sale since 2024CEO sold ~$1.91M of MLYS shares in the open market

What came next

  1. Oct 16, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.”
  2. Oct 27, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement
  3. Oct 29, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On October 29, 2026, Derek DiRocco, Ph.D. informed the Board of Directors (the Board) of the Company of his decision to resign from the Board, effective as of December 31, 2026.”
View the official recordSEC Form 144

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Mineralys Therapeutics

For Mineralys Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MLYS page.

How this filing works

Explore the data

Common questions

Which Mineralys Therapeutics (MLYS) insider traded, and how much?

Rodman David Malcom, Officer at Mineralys Therapeutics, filed to sell ~$78K of Mineralys Therapeutics shares. 3,542 shares, Form 144 notice of a planned sale.

When did it happen, and when was it made public?

Planned for: Oct 13, 2026. Notice filed: Oct 13, 2026.

What stands out in this filing?

The planned sale is less than 0.01% of the company's shares outstanding. How the shares were acquired, per the notice: Exercise of employee stock options. The notice says the shares were received as pay (stock awards or options).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Mineralys Therapeutics recently?

For Mineralys Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the MLYS page.

Does this mean MLYS stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Mineralys Therapeutics

Everything OQRO holds on this company is on its MLYS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data